A new hemoglobin-testing device developed by Irvine-based Masimo has been cleared for use by the FDA. The Pronto-7 was created for fast and accurate noninvasive hemoglobin spot-check testing.
"Noninvasive hemoglobin testing at the point-of-care offers a giant leap forward in our ability to tackle the global burden of anemia,” says Dr. Aryeh Shander, president-elect of the Society for the Advancement of Blood Management. “The beauty of immediate, noninvasive hemoglobin testing is that it will allow more patients to be assessed, so their physician can determine additional test options and initiate potentially lifesaving treatment."
Traditional hemoglobin testing requires poking the patient for a blood sample, and then sending it to the lab for analysis. This palm-size device provides results in less than one minute. It also has embedded Bluetooth communication capabilities that make wireless printing and emailing of results possible.
American Diabetes Association honors Fountain Valley Regional
Allergan honored for its healthy company culture and medical benefits
McCarthy Building Cos. completes major step in local hospital’s expansion